Business Description
Abpro Holdings Inc. is a biotechnology company based in Woburn, Massachusetts, focused on developing advanced antibody-based treatments for cancer and eye diseases. The company uses its proprietary platforms to discover and engineer multi-specific antibodies, which are designed to target multiple disease-driving proteins at once, improving their effectiveness over conventional therapies. Its leading drug candidates target aggressive cancers such as breast, gastric, and liver cancer, as well as serious vision-threatening conditions like diabetic macular edema and wet age-related macular degeneration. Abpro works alongside strategic partners Celltrion Inc. and Abpro Bio International Inc. to advance its pipeline.
